Works Cited

1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978.

2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537-544.

3. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17(1):39-57.

4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.

5. Parish SH, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437-447.

6. Giraldi A, Rellini AH, Pfaus J, Laan E. Female sexual arousal disorders. J Sex Med. 2013;10(1):58-73.

7. Kingsberg SA, Woodard T. Female sexual dysfunction: focus on low desire. Obstet Gynecol. 2015;125(2):477-486.

8. Angel K. Contested psychiatric ontology and feminist critique: female sexual dysfunction and the Diagnostic and Statistical Manual. Hist Human Sci. 2012;25(4):3-24.

9. Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014;11(6):1392-1422.

10. Jannini EA, Isidori AM, Aversa A, Lenzi A. Althof SE. Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. J Sex Med. 2013;10(10):2359-2369.

11. Mercer CH. Sexual behaviour. Medicine (Abingdon). 2014;42(6):291-293.

12. Marnash ML, Casey PM. Understanding women's sexual health: a case-based approach. Mayo Clin Proc. 2008;83(12):1382-1387.

13. Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4 Pt 2):1598-1607.

14. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61.

15. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460-463.

16. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology. 1999;54(6):1073-1077.

17. Tsertsvadze A, Yazdi F, Fink HA, et al. Diagnosis and Treatment of Erectile Dysfunction. Evidence Report/Technology Assessment No.171. Rockville, MD: Agency for Healthcare Research and Quality; 2009.

18. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4(1):57-65.

19. Giuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int. 2008;102(6):668-675.

20. Segraves RT, Balon R. Antidepressant-induced sexual dysfunction in men. Pharmacol Biochem Behav. 2014;121:132-137.

21. Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatment on sexual function in patients with schizophrenia: 12-month result from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006;21(4):251-258.

22. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.

23. Dohle GR, Arver S, Bettocchi C, et al. Guidelines on Male Hypogonadism. Available at http://uroweb.org/wp-content/uploads/18-Male-Hypogonadism_LR1.pdf. Last accessed February 10, 2017.

24. Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009;19(5):373-382.

25. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002;22(2):109-114.

26. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050-1057.

27. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28(Suppl 1):69-82.

28. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28(Suppl 2):109-123.

29. Traish AM, Ashwini M, Giordano N. The Dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367-379.

30. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872-884.

31. Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract. 2012;18(6):965-975.

32. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-1753.

33. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9(11):2927-2932.

34. Hogan C, Le Noury J, Healy D, Mangin D. One hundred and twenty cases of enduring sexual dysfunction following treatment.Int J Risk Saf Med. 2014;26(2):109-116.

35. Sexual Medicine Society of North America. 5-Alpha Reductase Inhibitors and Sexual Side Effects. Available at http://www.smsna.org/V1/index.php/about/position-statements. Last accessed February 10, 2017.

36. Shamloul R, Bella AJ. Impact of cannabis use on male sexual health. J Sex Med. 2011;8(4):971-975.

37. Bang-Ping J. Sexual dysfunction in men who abuse illicit drugs: a preliminary report. J Sex Med. 2009;6(4):1072-1080.

38. Chou NH, Huang YJ, Jiann BP. The impact of illicit use of amphetamine on male sexual functions. J Sex Med. 2015;12(8):1694-1702.

39. Derogatis LR, Psychiatric Times. Female Sexual Dysfunction. What We Know, What We Suspect, and Enduring Enigmas. Available at http://www.psychiatrictimes.com/articles/female-sexual-dysfunctionwhat-we-know-what-we-suspect-and-enduring-enigmas. Last accessed February 10, 2017.

40. Cao S, Yin X, Wang Y, Zhou H, Song F, Lu Z. Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLoS One. 2013;8(4):e60443.

41. Wu C, Zhang H, Gao Y, et al. The association of smoking and erectile dysfunction: results from the Fangchenggang Area Male Health and Examination Survey (FAMHES). J Androl. 2012;33(1):59-65.

42. Kovac JR. A critical analysis of the 2014 CUA guidelines for erectile dysfunction: is there more that can be done? Can Urol Assoc J. 2015;9(1-2):30-31.

43. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev. 2011;63(4):811-859.

44. Harte CB. Nicotine acutely inhibits erectile tumescence by altering heart rate variability. Urology. 2014;83(5):1093-1098.

45. Harte CB, Meston CM. Acute effects of nicotine on physiological and subjective sexual arousal in nonsmoking men: a randomized, double-blind, placebo-controlled trial. J Sex Med. 2008;5(1):110-121.

46. Harte CB, Meston CM. Association between smoking cessation and sexual health in men. BJU Int. 2012;109(6):888-896.

47. Brock G. Diagnosing erectile dysfunction could save your patient's life. Can Urol Assoc J. 2014;8(7-8):S151-S152.

48. Irwin DE, Milson I, Reilly K, et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med. 2008;5(12):2904-2910.

49. Laumann EO, Das A, Waite LJ. Sexual dysfunction among older adults: prevalence and risk factors from a nationally representative U.S. probability sample of men and women 57–85 years of age. J Sex Med. 2008;5(10):2300-2311.

50. Zohdy W. Clinical parameters that predict successful outcome in men with premature ejaculation and inflammatory prostatitis.J Sex Med. 2009;6(11):3139-3146.

51. Donatucci CF. Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med. 2006;3(Suppl 4):303-308.

52. El-Nashaar A, Shamloul R. Antibiotic treatment can delay ejaculation in patients with premature ejaculation and chronic bacterial prostatitis. J Sex Med. 2007;4(2):491-496.

53. Cosgrove DJ, Gordon Z, Bernie JE, et al. Sexual dysfunction in combat veterans with post-traumatic stress disorder. Urology. 2002;60(5):881-884.

54. Hatzimouratidis K, Eardley I, Giuliano F, et al. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Available at http://uroweb.org/wp-content/uploads/14-Male-Sexual-Dysfunction_LR.pdf. Last accessed February 10, 2017.

55. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the Health Professional's Follow-Up Study. Ann Int Med. 2003;139(3):161-168.

56. British Society for Sexual Medicine. Guidelines on the Management of Erectile Dysfunction. Available at http://www.bssm.org.uk/downloads/BSSM_ED_Management_Guidelines_2013.pdf. Last accessed February 10, 2017.

57. Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract. 2010;64(7):848-857.

58. Shin D, Pregenzer G Jr, Gardin JM. Erectile dysfunction: a disease marker for cardiovascular disease. Cardiol Rev. 2011;19(1):5-11.

59. Chew KK, Bremner A, Jamrozik K, Earle C, Stuckey B. Male erectile dysfunction and cardiovascular disease: Is there an intimate nexus? J Sex Med. 2008;5(4):928-934.

60. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22-26.

61. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108-113.

62. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23):2996-3002.

63. Araujo AB, Travison TG, Ganz P, et al. Erectile dysfunction and mortality. J Sex Med. 2009;6(9):2445-2554.

64. Vlachopoulos CV, Printzios-Terentes DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction. Circ Cardiovasc Qual Outcomes. 2013;6(1):99-109.

65. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-769.

66. Oguz F, Eltas A, Beytur A, Akdemir E, Uslu MÖ, Günes A. Is there a relationship between chronic periodontitis and erectile dysfunction? J Sex Med. 2013;10(3):838-843.

67. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778.

68. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306(11):1205-1214.

69. Goldstein I, Lurie AL, Lubisich JP. Bicycle riding, perineal trauma, and erectile dysfunction: data and solutions. Curr Urol Rep. 2007;8(6):491-497.

70. Marceau L, Kleinman K, Goldstein I, McKinlay J. Does bicycling contribute to the risk of erectile dysfunction? Results from the Massachusetts Male Aging Study (MMAS). Int J Impot Res. 2001;13(5):298-302.

71. Munarriz R, Uberoi J, Fantini G, Martinez D, Lee C. Microvascular arterial bypass surgery: long-term outcomes using validated instruments. J Urol. 2009;182:643-648.

72. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006;166(2):207-212.

73. Hidalgo-Tamola J, Chitaley K. Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med. 2009;6(4):916-926.

74. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6(5):1232-1247.

75. Glina S, Sharlip ID, Hellstrom WJ. Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med. 2013;10(1):115-119.

76. Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010;7(4 Pt 2):1627-1656.

77. Serefoglu EC, McMahon CG, Waldinger MD, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the Second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. Sex Med. 2014;2(2):41-59.

78. Zhang X, Gao J, Liu J, et al. Distribution and factors associated with four premature ejaculation syndromes in outpatients complaining of ejaculating prematurely. J Sex Med. 2013;10(6):1603-1611.

79. Gao J, Zhang X, Su P, et al. Prevalence and factors associated with the complaint of premature ejaculation and the four premature ejaculation syndromes: a large observational study in China. J Sex Med. 2013;10(7):1874-1881.

80. Basile Fasolo C, Mirone V, Gentile V, et al. Premature ejaculation: prevalence and associated conditions in a sample of 12,558 men attending the Andrology Prevention Week 2001: a study of the Italian Society of Andrology (SIA). J Sex Med. 2005;2(3):376-382.

81. Althof SE. Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation. J Urol. 2006;175(3 Pt 1):842-848.

82. Althof S. The psychology of premature ejaculation: therapies and consequences. J Sex Med. 2006;3(Suppl 4):324-331.

83. Rosen RC, Althof S. Impact of premature ejaculation: the psychological quality of life and sexual relationship consequences. J Sex Med. 2008;5(6):1296-1307.

84. Michetti P, Rossi R, Bonanno D, De Dominicis C, Iori F, Simonelli C. Dysregulation of emotions and premature ejaculation (PE): alexithymia in 100 outpatients. J Sex Med. 2007;4(5):1462-1467.

85. Porst H, McMahon C, Althof S, et al. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analysis of two phase III dapoxetine trials. J Sex Med. 2010;7(6):2231-2242.

86. Ozturk B, Cetinkaya M, Saglam H, Adsan O, Akin O, Memis A. Erectile dysfunction in premature ejaculation. Arch Ital Urol Androl. 1997;69(3):133-136.

87. Rowland D, Patrick D, Rothman M, Gagnon D. The psychological burden of premature ejaculation. J Urol. 2007;177(3):1065-1070.

88. Symonds T, Roblin D, Hart K, Althof S. How does premature ejaculation impact a man's life? J Sex Marital Ther. 2003;29(5):361-370.

89. Graziottin A, Althof S. What does premature ejaculation mean to the man, the woman, and the couple? J Sex Med. 2011;8(Suppl 4):304-309.

90. Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol. 2003;170(2 Pt 2):S6-S13.

91. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision. Arlington, VA: American Psychiatric Association; 2000.

92. Waldinger M, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. A multinational population survey of intravaginal ejaculation latency time. J Sex Med. 2005;2(4):292-297.

93. Waldinger M, McIntosh J, Schweitzer DH. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. J Sex Med. 2009;6(10):2888-2895.

94. Althof S, Abdo C, Dean J, et al. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med. 2010;7(9):2947-2969.

95. Kennedy SH, Dugré H, Defoy I. A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. Int Clin Psychopharmacol. 2011;26(3):151-158.

96. Moncada I, Martínez-Jabaloyas JM, Rodriguez-Vela L, et al. Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. J Sex Med. 2009;6(12):3469-3477.

97. Loran OB, Ströberg P, Lee SW, et al. Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt. J Sex Med. 2009;6(10):2826-2835.

98. Chevret-Méasson M, Lavallée E, Troy S, Arnould B, Oudin S, Cuzin B. Improvement in quality of sexual life in female partners of men with erectile dysfunction treated with sildenafil citrate: findings of the Index of Sexual Life (ISL) in a couple study.J Sex Med. 2009;6(3):761-769.

99. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.J Sex Med. 2013;10(6):1612-1627.

100. Bella AJ, Lee JC, Carrier S, Bénard F, Brock GB. 2015 CUA Practice guidelines for erectile dysfunction. Can Urol Assoc J. 2015;9(1-2):23-29.

101. American Urological Association Education and Research, Inc. The Management of Erectile Dysfunction: An Update. Available at https://www.auanet.org/common/pdf/education/clinical-guidance/Erectile-Dysfunction.pdf. Last accessed February 10, 2017.

102. Althof S, Rosen R, Symonds T, Mundayat R, May K, Abraham L. Development and validation of a new questionnaire to assess sexual satisfaction, control and distress associated with premature ejaculation. J Sex Med. 2006;3(3):465-475.

103. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The premature ejaculation profile: validation of self-reported outcome measures for research and practice. BJU Int. 2008;103(3):358-367.

104. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression: two questions are as good as many.J Gen Intern Med. 1997;12(7):439-445.

105. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol. 2002;168(2):615-620.

106. Yang M, Ni X, Sontag A, Litman HJ, Rosen RC. Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: validation of an anchor-based treatment responder classification. J Sex Med. 2013;10(12):3029-3037.

107. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822-830.

108. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319-326.

109. Rosen RC, Fisher WA, Beneke M, Homering M, Evers T. The COUPLES Project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment. BJU Int. 2007;99(4):849-859.

110. Derby CA, Araujo AB, Johannes CB, Feldman HA, McKinlay JB. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. Int J Impot Res. 2000;12(4):197-204.

111. Swindle RW, Cameron AE, Lockhart DC, Rosen RC. The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav. 2004;33(1):19-30.

112. Cappelleri JC, Althof SE, Siegel RL, Shpilsky A, Bell SS, Duttagupta S. Development and validation of the Self-Esteem and Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res. 2004;16(1):30-38.

113. Althof SE, Corty EW, Levine SB, et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53(4):793-799.

114. American Urological Association. AUA Position Statement on Testosterone Therapy. Available at http://www.auanet.org/education/testosterone-therapy.cfm. Last accessed February 10, 2017.

115. Paduch DA, Brannigan RE, Fuchs EF, et al. White Paper: The Laboratory Diagnosis of Testosterone Deficiency. Available at https://www.auanet.org/common/pdf/education/clinical-guidance/Testosterone-Deficiency-WhitePaper.pdf. Last accessed February 10, 2017.

116. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30(1):1-9.

117. Schmidt HM, Munder T, Gerger H, et al. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis. J Sex Med. 2014;11(6):1376-1391.

118. Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med. 2013;10(1):120-129.

119. Glina S, Ghanem H. SOP: corpus cavernosum assessment (cavernosography/cavernosometry). J Sex Med. 2013;10(1):111-114.

120. Giuliano F, Rowland DL. Standard operating procedures for neurophysiologic assessment of male sexual dysfunction. J Sex Med. 2013;10(5):1205-1211.

121. Galletly C, Lechuga J, Layde JB, Pinkerton S. Sexual health curricula in U.S. medical schools: current educational objectives.Acad Psychiatry. 2010;34(5):333-338.

122. Kim ED, Owen RC, White GS, Elkelany OO, Rahnema CD. Endovascular treatment of vasculogenic erectile dysfunction. Asian J Androl. 2015;17:40-43.

123. Kim ED. Erectile Dysfunction. Available at http://emedicine.medscape.com/article/444220-overview. Last accessed February 10, 2017.

124. Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2009;151(9):639-649.

125. Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-250.

126. Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.BJU Int. 2009;103(9):1212-1217.

127. Sperling H, Gittelman M, Norenberg C, Ulbrich E, Ewald S. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J Sex Med. 2011;8(1):261-271.

128. Heinig R, Weimann B, Dietrich H, Böttcher MF. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin Drug Investig. 2011;31(1):27-41.

129. Wirostko BM, Tressler C, Hwang LJ, Burgess G. Laties AM. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ. 2012;344:e554.

130. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005;45(9):987-1003.

131. Francis SH, Morris GZ, Corbin JD. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res. 2008;20(4):333-342.

132. Burke RM, Evans JD. Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag. 2012;8:517-523.

133. Vivus, Inc. Stendra-Avanafil Tablet: Prescribing Information. Mountain View, CA 94041.

134. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804-814.

135. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med. 2009;6(3):658-674.

136. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2):214-222.

137. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology. 2004;64(5):998-1003.

138. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004;172(5 Pt 1):1935-1940.

139. Eardley I, Montorsi F, Jackson G, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int. 2007;100(1):122-129.

140. Safarinejad MR. Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. Int J Impot Res. 2006;18(6):550-558.

141. Goldstein I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res. 2000;12(Suppl 1):S75-S80.

142. Goldstein I, Carson C, Rosen R, Islam A. Vasomax for the treatment of male erectile dysfunction. World J Urol. 2001;19(1):51-56.

143. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53(3):417-450.

144. von Keitz A, Stroberg P, Bukofzer S, Mallard N, Hibberd M. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int. 2002;89(4):409-415.

145. Hagemann JH, Berding G, Bergh S, et al. Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction. Eur Urol. 2003;43(4):412-420.

146. Stryjer R, Spivak B, Strous RD, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2009;32(2):82-84.

147. Taneja R. A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study. J Sex Med. 2007;4(4 Pt 2):1136-1141.

148. Nickel M, Moleda D, Loew T, Rother W, Pedrosa Gil F. Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. Int J Impot Res. 2007;19(1):104-107.

149. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-1106.

150. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59.

151. Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755-759.

152. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142.

153. Bschleipfer T, Cimniak HU, Beckert R, Hauck EW, Weidner W, Sparwasser C. Possible hemodynamic pathways of intraurethral prostaglandin-E1 (MUSE). Int J Impot Res. 2004;16(4):365-368.

154. Peterson CA, Bennett AH, Hellstrom WJ, et al. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J Urol. 1998;159(5):1523-1527.

155. Hellstrom WJ, Bennett AH, Gesundheit N, et al. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology. 1996;48(6):851-856.

156. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1-7.

157. Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology. 2000;55(4):477-480.

158. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334(14):873-877.

159. Sandhu D, Curless E, Dean J, et al. A double blind, placebo controlled study of intracavernosal VIP and phentolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res. 1999;11(2):91-97.

160. Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65(1):99-112.

161. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).J Sex Med. 2011;8(1):284-293.

162. Spitzer M, Basaria S, Travison TG, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157(10):681-691.

163. De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol. 1998;138(3):286-293.

164. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997;15(1):78-82.

165. Montague DK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am. 2011;38(2):217-225.

166. Jain S, Terry TR. Penile prosthetic surgery and its role in the treatment of end-stage erectile dysfunction: an update. Ann R Coll Surg Engl. 2006;88(4):343-348.

167. Rajpurkar A, Dhabuwala CB. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. J Urol. 2003;170(1): 159-163.

168. Lewis RW. Long-term results of penile prosthetic implants. Urol Clin North Am. 1995;22(4):847-856.

169. Mulhall JP, Ahmed A, Branch J, Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery.J Urol. 2003;169(4):1429-1433.

170. Nascimento NR, Lessa LM, Kerntopf MR, et al. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. Proc Natl Acad Sci USA. 2006;103(1):218-223.

171. Salway JG, Whitehead L, Finnegan JA, Karunanayaka A, Barnett D, Payne RB. Effect of myo-inositol on peripheral-nerve function in diabetes. Lancet. 1978;2(8103):1282-1284.

172. Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA. Folic acid improves endothelial dysfunction in type 2 diabetes: an effect independent of homocysteine-lowering. Vasc Med. 2006;11(2):101-109.

173. Agostini R, Rossi F, Pajalich R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2006;10(5):247-250.

174. Sansalone S, Leonardi R, Antonini G, et al. Alga Ecklonia bicyclis, Tribulus terrestris, and glucosamine oligosaccharide improve erectile function, sexual quality of life, and ejaculation function in patients with moderate mild-moderate erectile dysfunction: a prospective, randomized, placebo-controlled, single-blinded study. Biomed Res Int. 2014;121396:1-7.

175. Iacono F, Prezioso D, Illiano E, Romeo G, Ruffo A, Amato B. Sexual asthenia: Tradamixina versus tadalafil 5 mg daily. BMC Surg. 2012;12(Suppl 1):S23.

176. Giuliano F, Clèment P. Pharmacology for the treatment of premature ejaculation Pharmacol Rev. 2012;64(3):621-644.

177. McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol. 1999;161(6):1826-1830.

178. Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol. 2004;46(4):510-515.

179. McMahon CG. Long term results of treatment of premature ejaculation with selective serotonin re-uptake inhibitors. Int J Impot Res. 2002;14:S19.

180. Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs. 2007;67(4):547-568.

181. Aversa A, Francomano D, Bruzziches R, Natali M, Spera G, Lenzi A. Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation? Int J Impot Res. 2011;23(1):17-23.

182. Francomano D, Donini L, Lenzi A, Aversa A. Peripheral arterial tonometry to measure the effects of vardenafil on sympathetic tone in men with lifelong premature ejaculation. Int J Endocrinol. 2013;2013:394934.

183. Giuliano F. A novel treatment of premature ejaculation. Eur Urol Suppl. 2007;6(13):780-786.

184. Wieder JA, Brackett NL, Lynne CM, Green JT, Aballa TC. Anesthetic block of the dorsal penile nerve inhibits vibratory-induced ejaculation in men with spinal cord injuries. Urology. 2000;55(6):915-917.

185. Dinsmore W, Wylie M. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 minutes before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 2009;103(7):940-949.

186. Carson C, Wylie M. Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. J Sex Med. 2010;7(9):3179-3189.

187. Pu C, Yang L, Liu L, Yuan H, Wei Q, Han P. Topical anesthetic agents for premature ejaculation: a systematic review and meta-analysis. Urology. 2013;81(4):799-804.

188. Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 2004;93(7):1018-1021.

189. Hsieh T-C, Hollander AB, Walters RC, et al. 1495 Cabergoline for the treatment of male anorgasmia. J Urol. 2012;187(Suppl 4S):e605.

190. Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N. The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study. Neuropsychiatr Dis Treat. 2014;10:1571-1576.

191. Kalkavoura CS, Michopoulos I, Arvanitakis P, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21(4):332-341.

192. Dosa PI, Ward T, Walters MA, Kim SW. Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5HT2B receptor agonism. ACS Med Chem Lett. 2013;4(2):254-258.

193. U.S. Food and Drug Administration. Dostinex (Cabergoline) Tablets. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm266663.htm. Last accessed February 10, 2017.

194. Lam NT, Balachandran K. The mechanobiology of drug-induced cardiac valve disease. J Long Term Eff Med Implants. 2015;25 (1-2):27-40.

195. Molitch ME. Cabergoline and the heart: what's an endocrinologist to do? The Endocrinologist. 2014;111:14-15.

196. Singh J, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation. The Framingham Heart Study. Am J Cardiol. 1999;83(6):897-902.

197. Reid C, Anton-Culver H, Yunis C, Gardin JM. Prevalence and clinical correlates of isolated mitral, isolated aortic regurgitation, and both in adults aged 21 to 35 years (from the CARDIA Study). Am J Cardiol. 2007;99(6):830-834.

198. Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169(3):359-366.

199. Samson SL, Ezzat S. AACE/ACE disease state clinical review: dopamine agonists for hyperprolactinemia and the risk of cardiac valve disease. Endocr Pract. 2014;20(6):608-616.

200. Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015;3(11):906-913.

201. Corona G, Petrone L, Mannucci E, et al. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol. 2004;46(5):615-622.

202. Jannini EA, Lombardo F, Lenzi A. Correlation between ejaculatory and erectile dysfunction. Int J Androl. 2005;28(Suppl 2):S40-S45.

203. Asimakopoulos AD, Miano R, Finazzi Agrò E, et al. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis. J Sex Med. 2012;9(9):2404-2416.

204. Althof S. Sexual therapy in the age of pharmacotherapy. Ann Rev Sex Res. 2006;17(1):116-132.

205. Althof S. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res. 2002;14(Suppl 1):S99-S104.

206. Perelman MA. A new combination treatment for premature ejaculation: a sex therapist's perspective. J Sex Med. 2006;3(6):1004-1012.

207. Abdo CH, Afif-Abdo J, Otani F, Machado AC. Sexual satisfaction among patients with erectile dysfunction treated with counseling, sildenafil, or both. J Sex Med. 2008;5(7):1720-1726.

208. Aubin S, Heiman JR, Berger RE, Murallo AV, Yung-Wen L. Comparing sildenafil alone vs. sildenafil plus brief couple sex therapy on erectile dysfunction and couples' sexual and marital quality of life: a pilot study. J Sex Marital Ther. 2009;35(2):122-143.

209. Conaglen HM, Conaglen JV. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12- to 24-month follow-up after a 6-month free trial. J Sex Med. 2012;9(3):857-865.

210. Goldstein I, Mulhall JP, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T. The erection hardness score and its relationship to successful sexual intercourse. J Sex Med. 2008;5(10):2374-2380.

211. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-843.

212. O'Leary MP, Althof SE, Cappelleri JC, et al. Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol. 2006;175(3 Pt 1):1058-1062.

213. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978-2984.

214. Bradford A. Inhibited sexual desire in women. In: Grossman LR, Walfish S (eds). Translating Psychological Research into Practice. New York, NY: Springer; 2014: 515-518.

215. Jannini E, Simonelli C, Lenzi A. Sexological approach to ejaculatory dysfunction. Int J Androl. 2002;25(6):317-323.

216. Waldinger M. Premature ejaculation: different pathophysiologies and etiologies determine its treatment. J Sex Marital Ther. 2008;34(1):1-13.

217. Meston CM, Hull E, Levin RJ, Sipski M. Disorders of orgasm in women. J Sex Med. 2004;1(1):66-68.

218. Ayonrinde O. Importance of cultural sensitivity in therapeutic transactions: considerations for healthcare providers. Dis Manage Health Outcomes. 2003;11(4):233-248.

219. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;24(2): 78-85.

220. National Council on Interpreting in Health Care, Inc. National Standards for Healthcare Interpreter Training Programs. Available at http://www.ncihc.org/assets/documents/publications/National_Standards_5-09-11.pdf. Last accessed February 9, 2017.

221. Lynch EW. Developing cross-cultural competence. In: Lynch EW, Hanson MJ (eds). A Guide for Working with Children and their Families: Developing Cross-Cultural Competence. 4th ed. Baltimore, MD: Paul H. Brookes Publishing, Co.; 2011: 41-78.

222. Tribe R. Working with interpreters in mental health. Int J Cult Ment Health. 2009;2(2):92-101.

223. Dysart-Gale D. Clinicians and medical interpreters: negotiating culturally appropriate care for patients with limited English ability. Fam Community Health. 2007;30(3):237-246.

224. Raval H, Smith J. Therapists' experiences of working with language interpreters. Int J Ment Health. 2003;32(2):6-31.

225. Peixoto MM, Nobre P. “Macho” beliefs moderate the association between negative sexual episodes and activation of incompetence schemas in sexual context, in gay and heterosexual men. J Sex Med. 2017; [Epub ahead of print].

226. Huang YP, Chen B, Yao FJ, et al. Weaker masturbatory erection may be a sign of early cardiovascular risk associated with erectile dysfunction in young men without sexual intercourse. J Sex Med. 2014;11(6):1519-1526.

227. Park BY, Wilson G, Berger J, et al. Is Internet pornography causing sexual dysfunctions? A review with clinical reports. Behav Sci (Basel). 2016;6(3):e17.

228. Sun C, Bridges A, Johnason J, Ezzell M. Pornography and the male sexual script: an analysis of consumption and sexual relations. Arch Sex Behav. 2014;45(4):1-12.

229. Hilton DL. Pornography addiction: a supranormal stimulus considered in the context of neuroplasticity. Socioaffective Neurosci Psychol. 2013;3:20767.

230. Negash S, Sheppard NVN, Lambert NM, et al. Trading later rewards for current pleasure: pornography consumption and delay discounting. J Sex Res. 2016;53(6):689-700.

231. Banca P, Morris LS, Mitchell S, et al. Novelty, conditioning and attentional bias to sexual rewards. J Psychiatr Res. 2016;72:91-101.

232. Schomaker J, Meeter M. Short- and long-lasting consequences of novelty, deviance and surprise on brain and cognition. Neurosci Biobehav Rev. 2015;55:268-279.

233. Young Academic Urologists Men's Health Group, Fode M, Hatzichristodoulou G, Serefoglu EC, Verze P, Albersen M. Low-intensity shockwave therapy for erectile dysfunction: is the evidence strong enough? Nat Rev Urol. 2017;14(10):593-606.

Evidence-Based Practice Recommendations Citations

1. Marcell AV, Male Training Center for Family Planning and Reproductive Health. Preventive Male Sexual and Reproductive Health Care: Recommendations for Clinical Practice. Philadelphia, PA: Male Training Center for Family Planning and Reproductive Health; 2014. Summary retrieved from National Guideline Clearinghouse at https://guideline.gov/summaries/summary/48456. Last accessed February 21, 2017.

2. Clinical Effectiveness Group. 2013 UK National Guideline for Consultations Requiring Sexual History Taking. London: British Association for Sexual Health and HIV; 2013. Summary retrieved from National Guideline Clearinghouse at https://guideline.gov/summaries/summary/47031. Last accessed February 21, 2017.

3. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's Disease: AUA Guideline. Linthicum, MD: American Urological Association Education and Research, Inc.; 2015. Summary retrieved from National Guideline Clearinghouse at https://guideline.gov/summaries/summary/49269. Last accessed February 21, 2017.

4. Wallace Kazer M. Issues regarding sexuality. In: Boltz M, Capezuti E, Fulmer T, Zwicker D (eds). Evidence-Based Geriatric Nursing Protocols for Best Practice. 4th ed. New York, NY: Springer Publishing Company; 2012. Summary retrieved from National Guideline Clearinghouse at https://guideline.gov/summaries/summary/43928. Last accessed February 21, 2017.


Copyright © 2017 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.